1. Home
  2. TBPH vs RA Comparison

TBPH vs RA Comparison

Compare TBPH & RA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • RA
  • Stock Information
  • Founded
  • TBPH 2013
  • RA 2016
  • Country
  • TBPH United States
  • RA United States
  • Employees
  • TBPH N/A
  • RA 1260
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • RA Investment Managers
  • Sector
  • TBPH Health Care
  • RA Finance
  • Exchange
  • TBPH Nasdaq
  • RA Nasdaq
  • Market Cap
  • TBPH 699.0M
  • RA 711.7M
  • IPO Year
  • TBPH N/A
  • RA N/A
  • Fundamental
  • Price
  • TBPH $14.58
  • RA $13.45
  • Analyst Decision
  • TBPH Strong Buy
  • RA
  • Analyst Count
  • TBPH 4
  • RA 0
  • Target Price
  • TBPH $23.00
  • RA N/A
  • AVG Volume (30 Days)
  • TBPH 367.5K
  • RA 280.8K
  • Earning Date
  • TBPH 11-11-2025
  • RA 01-01-0001
  • Dividend Yield
  • TBPH N/A
  • RA 14.73%
  • EPS Growth
  • TBPH N/A
  • RA N/A
  • EPS
  • TBPH 0.26
  • RA N/A
  • Revenue
  • TBPH $77,205,000.00
  • RA N/A
  • Revenue This Year
  • TBPH $79.82
  • RA N/A
  • Revenue Next Year
  • TBPH N/A
  • RA N/A
  • P/E Ratio
  • TBPH $56.32
  • RA N/A
  • Revenue Growth
  • TBPH 24.49
  • RA N/A
  • 52 Week Low
  • TBPH $7.88
  • RA $11.89
  • 52 Week High
  • TBPH $15.15
  • RA $17.32
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 60.51
  • RA 53.49
  • Support Level
  • TBPH $14.00
  • RA $13.17
  • Resistance Level
  • TBPH $14.87
  • RA $13.54
  • Average True Range (ATR)
  • TBPH 0.50
  • RA 0.11
  • MACD
  • TBPH -0.02
  • RA 0.01
  • Stochastic Oscillator
  • TBPH 62.00
  • RA 75.68

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About RA Brookfield Real Assets Income Fund Inc.

Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.

Share on Social Networks: